AT Bancorp Takes Position in Alexion Pharmaceuticals, Inc. (ALXN)

AT Bancorp acquired a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,534 shares of the biopharmaceutical company’s stock, valued at approximately $3,094,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can increased its stake in shares of Alexion Pharmaceuticals by 2.8% in the third quarter. Great West Life Assurance Co. Can now owns 160,951 shares of the biopharmaceutical company’s stock valued at $19,703,000 after buying an additional 4,420 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Alexion Pharmaceuticals by 2.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 34,543 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 879 shares in the last quarter. DnB Asset Management AS boosted its position in Alexion Pharmaceuticals by 51.0% in the third quarter. DnB Asset Management AS now owns 29,908 shares of the biopharmaceutical company’s stock worth $3,665,000 after buying an additional 10,100 shares during the last quarter. World Asset Management Inc boosted its position in Alexion Pharmaceuticals by 2.0% in the third quarter. World Asset Management Inc now owns 21,946 shares of the biopharmaceutical company’s stock worth $2,689,000 after buying an additional 429 shares during the last quarter. Finally, Synovus Financial Corp boosted its position in Alexion Pharmaceuticals by 2.8% in the third quarter. Synovus Financial Corp now owns 16,109 shares of the biopharmaceutical company’s stock worth $1,976,000 after buying an additional 442 shares during the last quarter. Institutional investors and hedge funds own 94.98% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 2.43% on Friday, hitting $113.84. 2,613,737 shares of the stock traded hands. The stock has a market cap of $25.56 billion, a price-to-earnings ratio of 54.24 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52 week low of $109.12 and a 52 week high of $157.02. The firm’s 50 day moving average is $121.19 and its 200 day moving average is $124.94.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.33. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. During the same period last year, the company posted $1.11 EPS. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.31 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “AT Bancorp Takes Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/05/19/at-bancorp-takes-position-in-alexion-pharmaceuticals-inc-alxn-updated.html.

ALXN has been the subject of a number of analyst reports. Leerink Swann set a $208.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 13th. Oppenheimer Holdings Inc. initiated coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, February 8th. They issued a “hold” rating for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $158.00 price target (down previously from $166.00) on shares of Alexion Pharmaceuticals in a research report on Sunday, February 19th. JPMorgan Chase & Co. set a $170.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 7th. Finally, Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $168.10.

In related news, Director Leonard Bell sold 3,978 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $131.96, for a total transaction of $524,936.88. Following the sale, the director now directly owns 391,910 shares in the company, valued at approximately $51,716,443.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Clare Carmichael sold 2,179 shares of the firm’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $131.66, for a total transaction of $286,887.14. Following the transaction, the executive vice president now owns 33,980 shares of the company’s stock, valued at approximately $4,473,806.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,476 shares of company stock worth $1,504,601. 4.41% of the stock is currently owned by corporate insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply